TA Associates Makes Strategic Growth Investment in Synokem Pharmaceuticals
January 18, 2023
TA Associates completed a strategic growth investment in Synokem Pharmaceuticals Ltd., with Synokem's founders remaining shareholders. The investment will support Synokem—an India-based CDMO with operations in New Delhi and manufacturing/R&D in Haridwar—to drive organic growth and pursue strategic acquisitions and capability expansion for domestic and international markets.
- Buyers
- TA Associates
- Targets
- Synokem Pharmaceuticals Ltd.
- Industry
- Pharmaceuticals
- Location
- Delhi, India
- Transaction Type
- Growth capital
Explore More
Related Acquisitions
-
TA Associates Makes Strategic Growth Investment in Diatech Pharmacogenetics
April 26, 2023
Biotechnology
TA Associates has signed a definitive agreement to make a strategic growth investment in Diatech Pharmacogenetics, a Jesi, Italy–based developer and manufacturer of molecular diagnostics for precision oncology. Minority investor Alto Partners will fully exit while Diatech's founder and management retain majority ownership; the capital will support product development and international expansion.
-
TA Associates Makes Majority Growth Investment in Elos Medtech
June 11, 2021
Medical Devices
TA Associates completed a majority growth investment in Elos Medtech AB, acquiring a controlling stake via a public offer that tendered approximately 79.5% of the company’s share capital. Elos Medtech, headquartered in Gothenburg, Sweden, is a full-service contract development and manufacturing organization (CDMO) serving dental, orthopaedic and life science customers with facilities in Sweden, Denmark, China and the U.S.
-
TA Associates Completes Strategic Growth Investment in Vee Healthtek
November 18, 2024
Healthcare Services
TA Associates completed a strategic growth investment in Vee Healthtek to support the company's expansion of technology-enabled services for healthcare organizations. The partnership will help Vee Healthtek enhance its technology capabilities, expand offerings (organically and via M&A) across revenue cycle management, health information management, analytics, risk adjustment and claims management; financial terms were not disclosed.
-
TA Associates Makes Strategic Growth Investment in HealthMark Group
July 30, 2025
Healthcare Services
TA Associates has made a strategic growth investment in HealthMark Group, a Dallas-based provider of clinical information exchange solutions. Management and existing investor Ridgemont Equity Partners rolled meaningful stakes as TA becomes the new lead investor to accelerate HealthMark's growth, expand capabilities, and broaden market reach.
-
TA Associates Makes Strategic Growth Investment in Technosylva
August 15, 2022
Cloud & SaaS
TA Associates has signed a definitive agreement to make a strategic growth investment in Technosylva, a provider of wildfire simulation, risk analysis and incident-response SaaS solutions. The investment will accelerate product development and adoption of Technosylva’s Wildfire Analyst, fiResponse and Tactical Analyst platforms; the deal is expected to close in Q3 2022 and financial terms were not disclosed.
-
Synova Capital Invests in Charnwood Molecular
January 1, 2020
Biotechnology
Synova Capital has completed a significant growth investment into Charnwood Molecular to support the company's next phase of expansion. The funding will be used to accelerate Charnwood’s development of higher‑value chemistry, broaden its scientific service offering, and pursue selective acquisitions to expand capabilities and address strong demand from pharma and biotech clients.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.